|
| |
| | BioMed Central Full text The Renin-Angiotensin-Aldosterone system in patients with depression compared to controls ... |
 | | Other functional systems involved in aldosterone release, which have been reported to be changed in depression include arginin vasopressin [ 50, 51 ] and prostaglandins, especially prostaglandin E2 Despite the hyperaldosteronism no changes in electrolyte concentrations could be found in this study. | | | Therefore, it is unlikely that changes in the sympathetic system alone contribute to the increase in aldosterone. | | | The Renin-Angiotensin-Aldosterone system in patients with depression compared to controls – a sleep endocrine study |
|
http://www.biomedcentral.com/1471-244X/3/15
|
|
| |
| | Endotext.com - Adrenal Physiology And Diseases, Aldosterone Excess |
| | This is based on studies that have found an exaggerated aldosterone response to infused angiotensin II in BAH patients (25). | | | Other potassium-sparing diuretics, such as triamterene or amiloride have been used, but usually are not as effective as spironolactone (48). | | | Surgery is most often the treatment of choice for APA, and is often performed with laporoscopic techniques, thereby reducing patient recovery time and hospital cost. |
|
http://www.endotext.com/adrenal/adrenal23/adrenal23.htm
|
|
| |
| | [No title] |
| | Review of surgical management of aldosterone secreting tumours of the adrenal cortex. | | | Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects. | | | Actions of vasoactive intestinal peptide on the rat adrenal zona glomerulosa. |
|
http://hair-loss-stop.com/ref-aldosterone/aldosterone-refs.html
|
|
| |
| | To Save Money on Aldosterone Click Here for Aldosterone Discount Sources. |
| | The Renin-Angiotensin- Aldosterone system in patients with depression compared to controls — a sleep endocrine study Abstract Background Hypercortisolism as a sign of hypothamamus-pituitary-... | | | You may qualify to get Aldosterone and your other prescription drugs for free. | | | The Renin-Angiotensin- Aldosterone system in patients with depression compared to controls — a sleep endocrine study |
|
http://www.institutedc.org/res/3/Aldosterone.html
|
|
| |
| | Renin / Angiotensin / Aldosterone / ANP: |
| | Aldosterone is the most potent naturally occurring mineralocorticoid and accounts for most of the above actions in humans. | | | This system is so sensitive that even a change from lying down to sitting up will increase renin secretion and lead to Na and H | | | Aldosterone is 25 times more potent than 11-deoxycorticosterone (DOC) and 1000 times more potent than cortisol or corticosterone. |
|
http://www.gravitywaves.com/chemistry/CHE452/22_RenAngioAldoANP18.htm
|
|
| |
| | Dekker.com - Renin–Angiotensin–Aldosterone System Loci and Multilocus Interactions in Young-Onset ... |
| | Thus, we studied the association of singe locus or multilocus interactions with young-onset essential hypertension. | | | Dekker.com - Renin–Angiotensin–Aldosterone System Loci and Multilocus Interactions in Young-Onset Essential Hypertension | | | Renin–Angiotensin–Aldosterone System Loci and Multilocus Interactions in Young-Onset Essential Hypertension |
|
http://www.dekker.com/servlet/product/DOI/101081CEH120017932
|
|
| |
| | Journal of the Renin-Angiotensin-Aldosterone System (JRAAS) |
| | As a result of these studies, research in the laboratory and clinic is rapidly exploring the significance of these systems in cardiovascular and non-cardiovascular diseases. | | | In the last decade the renin-angiotensin-aldosterone system (RAAS) and other peptidergic systems, such as atrial natriuretic peptides and endothelin, have become an increasingly important focus of basic cardiovascular research. | | | Results of clinical trials of drugs inhibiting the systems in the treatment of hypertension, renal disease, heart failure, post-myocardial infarction and diabetes as well as new areas of clinical research into the possible value of these agents in new indications such as maintenance of cognitive function |
|
http://www.jraas.com/
|
|
| |
| | NHLBI-ISH HBP Symposium - Renin-Angiotensin-Aldosterone System |
| | For the rest, we need more fundamental information about the biology of the renin-angiotensin-aldosterone system in human subjects. | | | Please send us your feedback, comments, and questions | | | Additional long-term controlled clinical trials are needed to clarify the benefits and risks of cardiovascular outcomes associated with blood pressure reduction induced by antihypertensive agents that antagonize components of the renin-angiotensin-aldosterone system in patients with multiple cardiovascular risk factors. |
|
http://www.nhlbi.nih.gov/meetings/ish/oparil.htm
|
|
| |
| | ACE Inhibition in Heart Disease |
| | Essential hypertension: renin and aldosterone, heart attack and stroke. | | | Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. | | | system with drugs, dramatically highlighting the many subtleties |
|
http://www.complab.nymc.edu/Medicine/ACEInhibition.htm
|
|
| |
| | PMID: 6354929 PMID: 6424258 Propecia in the long-term treatment of essential hypertension: changes in the ... |
| | PMID: 6354929 PMID: 6424258 Propecia in the long-term treatment of essential hypertension: changes in the renin-angiotensin-aldosterone system. | | | Propecia in the long-term treatment of essential hypertension: changes in the renin-angiotensin-aldosterone system. | | | Riegger GA, Steilner H, Hayduk K, Liebau G. We investigated changes in the renin-angiotensin-aldosterone system in seven patients with essential hypertension during treatment with captopril (SQ 14225) (300 to 450 mg/day) for 12 months. |
|
http://dreampharmaceuticals.com/ref-captopril/captopril-research-abs5.144.html
|
|
| |
| | Renin-angiotensin system - Wikipedia, the free encyclopedia |
| | The renin-angiotensin system is often manipulated clinically to treat | | | Angiotensin II has a variety of effects on the body: | | | Angiotensin I may have some minor activity, but angiotensin II is more potent. |
|
http://en.wikipedia.org/wiki/Renin-angiotensin_system
|
|
| |
| | aldosterone |
| | (News capsules: what's new in drug research and managed care pharmacy).(selective aldosterone inhibitor reduces blood pressure)(Brief Article) (Formulary) | | | Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: an Asian perspective from the RENAAL study. | | | New ACC/AHA Stemi Guidelines Urge Early and Long-Term Treatment With Aldosterone Blockade Therapy; Pfizer's INSPRA(R) (eplerenone) has the potential to save more lives. |
|
http://www.infoplease.com/ce6/sci/A0803163.html
|
|
| |
| | CCHO Publications - Childrens Hospital San Diego |
| | Young, N., Gardner, S. and Dennis, K. Responding to Alcohol and Other Drug Problems in Child Welfare: Weaving Together Policy and Practice. | | | Sobo, E., Andriese, S. Stroup, C., Morgan, D., and Kurtin, P.S. (March 25, 2000) Creating a Process Model for the Evaluation of Emergency Medical Service Systems. | | | Using state and local databases to monitor the impact of public policy and system changes: The San Diego experience. |
|
http://www.chsd.org/1411.cfm
|
|
| |
| | Simpson S. Does inhibition of the renin-angiotensin-aldosterone system reduce the risk of cardiovascular events? A ... |
| | Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. | | | The beneficial effects of angiotensin- converting enzyme inhibitors have been proven in patients with symptomatic and asymptomatic heart failure. | | | The HOPE study was designed to test the theory that inhibition of the renin-angiotensin-aldosterone system would reduce the risk of cardiovascular events. |
|
http://www.informedpharmacotherapy.com/Issue1/HopeEBPReview.htm
|
|
| |
| | NEJM -- The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease |
| | The renin-angiotensin-aldosterone system is stimulated significantly more in hypertensive patients with polycystic kidney disease than in comparable patients with essential hypertension. | | | To investigate this hypothesis, we measured plasma renin activity and aldosterone concentrations during short-term and long-term converting-enzyme inhibition in 14 patients with hypertension due to polycystic kidney disease, 9 patients with essential hypertension, 11 normotensive patients with polycystic kidney disease, and 13 normal subjects. | | | After six weeks of converting-enzyme inhibition, renal plasma flow increased (P less than 0.005), and both renal vascular resistance (P less than 0.007) and the filtration fraction (P less than 0.02) decreased significantly in the hypertensive patients with polycystic kidney disease but not in the patients with essential hypertension. |
|
http://content.nejm.org/cgi/content/short/323/16/1091
|
|
| |
| | Nesiritide Treatment Associated with Significantly Reduced In Hospital Mortality Rate |
| | NATRECOR® may affect renal function in susceptible patients. | | | In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with NATRECOR® may be associated with azotemia. | | | Higher doses of NATRECOR® increased the risk of hypotension and elevated creatinine. |
|
http://www.medicalnewstoday.com/medicalnews.php?newsid=13387
|
|
| |
| | Excess Catecholamine Syndrome and the renin angiotensin aldosterone system |
| | The unfavorable effects of a raised sympathetic activity can be shown in normal persons after reflex stimulation of the sympathetic nervous system. | | | Excess Catecholamine Syndrome and the renin angiotensin aldosterone system | | | In ongoing studies,the concept is examined that catecholamines, that are in excess to the physical activity, induce various reactions in the body which eventually contribute to the development of hypertension, insulin resistance, hypertriglyceridemia and hyperuricemia. |
|
http://cleverfood.com/cf10.htm
|
|
| |
| | Summary: Blood Pressure-Independent Atherogenic and Thromboembolic Mechanisms of the Renin-Angiotensin-Aldosterone ... |
| | Blood Pressure-Independent Atherogenic and Thromboembolic Mechanisms of the Renin-Angiotensin-Aldosterone System | | | Summary: Blood Pressure-Independent Atherogenic and Thromboembolic Mechanisms of the Renin-Angiotensin-Aldosterone System | | | Numerous studies have provided insight into the possible role of the renin-angiotensin-aldosterone system (RAAS) in the pathophysiology of atherosclerotic vascular disease and its thromboembolic complications. |
|
http://www.kup.at/journals/summary/817.html
|
|
| |
| | Renin-angiotensin system |
| | While the pathways for the renin-angiotensin system have been found in a number of tissues, the most important site for renin release is the kidney. | | | The renin-angiotensin system plays an important role in regulating blood volume, arterial pressure, and cardiac and vascular function. | | | Renin is an enzyme that acts upon a circulating substrate, angiotensinogen, that undergoes proteolytic cleavage to from the decapeptide angiotensin I. Vascular endothelium, particularly in the lungs, has an enzyme, angiotensin converting enzyme (ACE), that cleaves off two amino acids to form the octapeptide, angiotensin II (AII). |
|
http://www.oucom.ohiou.edu/CVPhysiology/BP015.htm
|
|
| |
| | BioMed Central Abstract The Renin-Angiotensin-Aldosterone System as a Target in Coronary Disease |
| | Therapy directed at RAAS overactivity is essential for normalizing the prognosis of most patients with atherosclerosis. | | | Aldosterone receptor blocking agents also improve cardiovascular structure, function, and prognosis. | | | The renin-angiotensin-aldosterone system (RAAS) plays a fundamental role in the development of atherosclerosis and adverse cardiovascular events. |
|
http://www.biomedcentral.com/1523-3804/5/124/abstract
|
|
| |
| | The renin-angiotensin-aldosterone system and Alzheimer s disease? Nutritional variation and cardiovascular risk factors ... |
| | Finally, this paper discusses very recent biological evidence that further supports a role for ACE1 and hypothesises a number of readily testable mechanisms by which the ACE1 enzyme and other components of the renin-angiotensin-aldosterone system may be implicated in increased risk and/or the progression of AD. | | | This role is suggested in terms of recent molecular genetic association evidence implicating the ACE1 insertion/deletion (indel) polymorphism, a more recent large haplotype study that greatly extends the ACE1 indel evidence and incorporates knowledge accrued from previous cardiovascular disease-focused ACE1 haplotype studies. | | | Dietary history of the participants was obtained using a standard questionnaire designed on the basis of a seven-day recall system. |
|
http://twinpharm.com/ref-lipoprotein/lipoprotein-research-abs4.923.html
|
|
| |
| | The renin-angiotensin-aldosterone system (RAAS) and its relation with calcium homeostasis in male obesity. |
| | BACKGROUND: The aim of our study was to determine whether alterations of the vitamin D-endocrine system and the renin-angiotensin-aldosterone system occur in male obesity and influence each other.MATERIAL/METHODS: 32 obese male subjects and 21 age-matched healthy male subjects were enrolled in the study. | | | Supine renin activity did not correlate with any parameters, whereas upright renin correlated with serum Mg and PTH. | | | Supine aldosterone correlated with serum total calcium, ionized calcium and supine renin activity, but not with other minerals, PTH or 25OHD, whereas upright aldosterone did not correlate with other parameters. |
|
http://obesity-2.viagenbio.com/obesity-research-abs.2001.html
|
|
| |
| | BioMed Central Abstract The Tissue Renin-Angiotensin-Aldosterone System in Diabetes Mellitus |
| | The contribution of the tissue RAS in disease pathogenesis has recently been the focus of much interest, and has prompted investigators to explore the use of high-dose RAS inhibition with monotherapy or combination therapy to provide a more complete blockade of the actions of angiotensin II, beyond lowering blood pressure. | | | The relationship between the renin-angiotensin system (RAS) and diabetic macrovascular and microvascular disease is well established. | | | There is now evidence to support this approach to maximize cardiovascular and renal protection. |
|
http://www.biomedcentral.com/1522-6417/6/98/abstract
|
|
| |
| | Season's Appreciations 1998, NEL Vol 20, Nos. 1/2, 1999. |
| | Siegelova J., Fiser B., Dusek J., Cornelissen G., Halberg F. Circadian variability of rate pressure product in hypertension with enalapril therapy. | | | Part II: Implanted hemodynamic monitors reveal broad chronomes potentially useful for guiding therapeutic interventions. | | | No part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or ortherwise, without prior written permission from the Editor-in-Chief. |
|
http://www.nel.edu/20_12/nel20_12%20Seasons98.htm
|
|
| |
| | Publications |
| | Repeated blood pressure measurements in a sample of Swedish twins: heritabilities and associations with polymorphisms in the renin- angiotensin-aldosterone system. |
|
http://www.mep.ki.se/twinreg/publications/index_en.html
|
|
| |
| | Energy Citations Database (ECD) Document #6257652 - Renin-angiotensin-aldosterone system and electrolyte ... |
| | Blood plasma aldosterone concentration and renin activity were studied in rats flow in space on the Cosmos 1129 satellite using radioimmunoassay techniques.^Immediately after the flight, the animals presented significant decreases in plasma renin activity, as compared to rats in the vivarium control and animals in the synchronous experiment.^R. Country of | | | 550601 -- Medicine-- Unsealed Radionuclides in Diagnostics ;550500 -- Metabolism; ;ALDOSTERONE-- RADIOIMMUNOASSAY;RENIN-- RADIOIMMUNOASSAY; BLOOD PLASMA;COMPARATIVE EVALUATIONS;ELECTROLYTES;KIDNEYS;METABOLISM;POTASSIUM;RATS;SODIUM;SPACE FLIGHT | | | Renin-angiotensin-aldosterone system and electrolyte metabolism in rat blood after flight aboard Cosmos-1129 biosatellite |
|
http://www.osti.gov/energycitations/product.biblio.jsp?osti_id=6257652
|
|
|
